These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 1413197

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Hallucinogenic mushrooms in Denmark].
    Holm JW, Ebbehøj NE, Fjeldberg IA.
    Ugeskr Laeger; 1997 Aug 18; 159(34):5116-8. PubMed ID: 9297322
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hallucinogenic mushrooms.
    Schwartz RH, Smith DE.
    Clin Pediatr (Phila); 1988 Feb 18; 27(2):70-3. PubMed ID: 3338231
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
    Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D.
    Hum Psychopharmacol; 2012 Jul 18; 27(4):352-63. PubMed ID: 22696164
    [Abstract] [Full Text] [Related]

  • 11. DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin.
    Gambaro V, Roda G, Visconti GL, Arnoldi S, Casagni E, Dell'Acqua L, Farè F, Paladino E, Rusconi C, Arioli S, Mora D.
    J Pharm Biomed Anal; 2016 Jun 05; 125():427-32. PubMed ID: 27021629
    [Abstract] [Full Text] [Related]

  • 12. Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.
    Beck O, Helander A, Karlson-Stiber C, Stephansson N.
    J Anal Toxicol; 1998 Jun 05; 22(1):45-9. PubMed ID: 9491968
    [Abstract] [Full Text] [Related]

  • 13. The danger of hallucinogenic mushrooms.
    Mills PR, Lesinskas D, Watkinson G.
    Scott Med J; 1979 Oct 05; 24(4):316-7. PubMed ID: 555819
    [Abstract] [Full Text] [Related]

  • 14. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
    Roberts CA, Osborne-Miller I, Cole J, Gage SH, Christiansen P.
    J Psychopharmacol; 2020 Sep 05; 34(9):999-1007. PubMed ID: 32674668
    [Abstract] [Full Text] [Related]

  • 15. Between prohibitions: patterns and meanings of magic mushroom use in the UK.
    Riley SC, Blackman G.
    Subst Use Misuse; 2008 Sep 05; 43(1):55-71. PubMed ID: 18189205
    [Abstract] [Full Text] [Related]

  • 16. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E.
    J Psychopharmacol; 2020 Jun 05; 34(6):612-622. PubMed ID: 32108529
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R, Anderson T, Maier LJ, Barratt MJ, Ferris JA, Winstock AR.
    J Psychopharmacol; 2022 Jan 05; 36(1):85-96. PubMed ID: 33591231
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR, Kaar S, Borschmann R.
    J Psychopharmacol; 2014 Jan 05; 28(1):49-54. PubMed ID: 24284475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.